Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342310 | 0.72 | CA2 (0.52) | CA2CA4CA5AALDH1A1NPC1 | |
| SCHEMBL1158061 | 0.68 | ALDH1A1 (0.47) | CA2CA4ALDH1A1HPGDNPC1 | |
| SCHEMBL30479079 | 0.63 | ALDH1A1 (0.74) | CA2CA4ALDH1A1HPGDMAPT | |
| SCHEMBL7347871 | 0.63 | ALDH1A1 (0.74) | CA2CA4ALDH1A1HPGDMAPT | |
| SCHEMBL27727903 | 0.62 | ALDH1A1 (0.41) | CA2CA4ALDH1A1HPGDMAPT | |
| SCHEMBL10634637 | 0.61 | CA2 (0.44) | CA2CA4CA5AALDH1A1NPC1 | |
| Phthalic Acid SCHEMBL29936501 | 0.60 | ALDH1A1 (0.78) | CA2CA4ALDH1A1HPGDMAPT | |
| Phthalic Acid SCHEMBL28484760 | 0.60 | ALDH1A1 (0.78) | CA2CA4ALDH1A1HPGDMAPT | |
| SCHEMBL61048 | 0.60 | HPGD (0.56) | CA2CA4CA5AALDH1A1HPGD | |
| SCHEMBL30043535 | 0.60 | HPGD (0.56) | CA2CA4CA5AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117083295-A | Neutralizing antibodies to IL-17A, fusion proteins thereof and uses thereof | 拉尼尔生物治疗公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-2236606-B1 | Ligational encoding of small molecules | NUEVOLUTION AS (DK) | 2013-11-06 | — | — | EP | disclosed |
| US-7915201-B2 | Ligational encoding of small molecules | NUEVOLUTION A/S (DK) | 2011-03-29 | — | — | US | disclosed |
| EP-2236606-A2 | Ligational encoding of small molecules | Nuevolution A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| EP-1608748-B1 | LIGATIONAL ENCODING OF SMALL MOLECULES | NUEVOLUTION AS (DK) | 2009-03-04 | — | — | EP | disclosed |
| US-20060246450-A1 | Ligational encoding of small molecules | NUEVOLUTION A/S (DK) | 2006-11-02 | — | — | US | disclosed |
| EP-1608748-A2 | LIGATIONAL ENCODING OF SMALL MOLECULES | Nuevolution A/S (DK) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083427-A2 | LIGATIONAL ENCODING OF SMALL MOLECULES | NUEVOLUTION A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
| US-20040063138-A1 | Polynucleotide sequencing method | MCGINNIS MALCOLM D (US) | 2004-04-01 | — | — | US | disclosed |
| US-6635419-B1 | Using target-specific primers which contain a binding segment and a mobility-reducing moiety; reacting with primer extension reagent; separating electrophoretically using a sieving matrix and detecting signal | APPLERA CORPORATION | 2003-10-21 | — | — | US | disclosed |
| EP-1159454-B1 | POLYNUCLEOTIDE SEQUENCING METHOD | APPLERA CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1159454-A2 | POLYNUCLEOTIDE SEQUENCING METHOD | PE Corporation (NY) (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000049178-A2 | POLYNUCLEOTIDE SEQUENCING METHOD | THE PERKIN-ELMER CORPORATION (US) | 2000-08-24 | — | — | WO | disclosed |
| US-6048974-A | NUCLEOTIDE SEQUENCES THAT SERVE AS CLAMPS FOR PREFERENTIALLY BINDING TO TARGET POLYNUCLEOTIDES FORMING STABLE CIRCULAR STRUCTURES | LYNX THERAPEUTICS, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5741643-A | CAPABLE OF SPECIFIC BINDING TO TARGET POLYNUCLEOTIDES | LYNX THERAPEUTICS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246450-A1 | Ligational encoding of small molecules | POLI, PCNA, LIG4 | CA2 3506/4885CA4 2657/4885CA5A 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.